Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Melanoma Stories

2014-03-27 08:33:21

ORPINGTON, England, March 27, 2014 /PRNewswire/ -- Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, announces positive top line results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT. In the study, over 250 patients with clinically suspicious lesions for basal cell carcinoma were scanned...

2014-03-26 12:26:20

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., March 26, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 45 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma compared with 28...

2014-03-24 08:29:37

LOS ANGELES, March 24, 2014 /PRNewswire/ -- Dermatologist, Dr. Peyman Ghasri, offers treatments for various types of skin cancer. Skin cancer is the most common type of cancer in the United States today. In fact, half of all those who live beyond 65 will suffer from some form of skin cancer. Early diagnosis offers the best prognosis for skin cancer treatment, but options are available to treat the various stages and types of cancer based on the patient's needs and the cancer's...

2014-03-22 20:20:22

Data presented at the Latest in Dermatology Research Symposia session of 72nd Annual Meeting of the American Academy of Dermatology DENVER, March 22, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy. The data are being presented at the Latest in...

2014-03-21 12:24:19

The SRT-100(TM) and SRT-100 Vision(TM) are used to treat a host of dermatological and oncological conditions with low-energy radiation therapy BOCA RATON, Fla., March 21, 2014 /PRNewswire/ -- Frost & Sullivan has recognized Sensus Healthcare with the 2014 North American award for New Product Innovation Leadership. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award...

2014-03-21 08:24:14

ORPINGTON, England, March 21, 2014 /PRNewswire/ -- Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, today announces positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology's 72nd Annual Meeting (AAD) in Denver, Colorado,...

2014-03-20 12:28:30

The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions MOUNTAIN VIEW, Calif., March 20, 2014 /PRNewswire/ -- Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation...

Cancer Drug Trial Suffers Another Setback
2014-03-20 11:52:30

Lee Rannals for redOrbit.com - Your Universe Online GlaxoSmithKline (GSK) said on Thursday that its cancer drug MAGE-A3 has failed its second test. The company said that the drug missed the first co-primary endpoints during the third phase of its study involving more than 2,000 lung cancer patients. The researchers found that the experimental therapy did not help patients live longer without their disease recurring. During the study, patients were given up to 13 intramuscular...

2014-03-20 08:30:04

The Jeffrey Epstein VI Foundation puts its support behind Congress' largest bill for Melanoma. NEW YORK, March 20, 2014 /PRNewswire/ -- One of Harvard's biggest investors, Jeffrey Epstein, and founder of Harvard's Program for Evolutionary Dynamics, has heralded congress' largest funding bill for melanoma research. The appropriations bill was for the Department of Defense's Peer-Reviewed Cancer Research Program (PRCRP) in the amount of $25 million, and is devoted to research for...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...